These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8593019)

  • 41. Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates.
    Thompson PA; Berg SL; Aleksic A; Kerr JZ; McGuffey L; Dauser R; Nuchtern JG; Hausheer F; Blaney SM
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):527-32. PubMed ID: 14997342
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.
    Klecker RW; Collins JM; Yarchoan RC; Thomas R; McAtee N; Broder S; Myers CE
    J Clin Pharmacol; 1988 Sep; 28(9):837-42. PubMed ID: 2852679
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex) in a nonhuman primate model.
    Widemann BC; Balis FM; Godwin KS; McCully C; Adamson PC
    Cancer Chemother Pharmacol; 1999; 44(6):439-43. PubMed ID: 10550563
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro immunotoxicity of +/- 2'-deoxy-3'-thiacytidine, a new anti-HIV agent.
    Lisignoli G; Monaco MC; Degrassi A; Toneguzzi S; Ricchi E; Costigliola P; Facchini A
    Clin Exp Immunol; 1993 Jun; 92(3):455-9. PubMed ID: 8390335
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates.
    Kilburn LB; Bonate PL; Blaney SM; McGuffey L; Nuchtern JG; Dauser R; Thompson P; Gibson BW; Berg SL
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):335-40. PubMed ID: 19043710
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole.
    Moore KH; Yuen GJ; Raasch RH; Eron JJ; Martin D; Mydlow PK; Hussey EK
    Clin Pharmacol Ther; 1996 May; 59(5):550-8. PubMed ID: 8646826
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs.
    Scott-Moncrieff JC; Chan TC; Samuels ML; Cook JR; Coppoc GL; DeNicola DB; Richardson RC
    Cancer Chemother Pharmacol; 1991; 29(1):13-8. PubMed ID: 1742843
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.
    Blaney SM; Takimoto C; Murry DJ; Kuttesch N; McCully C; Cole DE; Godwin K; Balis FM
    Cancer Chemother Pharmacol; 1998; 41(6):464-8. PubMed ID: 9554590
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates.
    Neville K; Parise RA; Thompson P; Aleksic A; Egorin MJ; Balis FM; McGuffey L; McCully C; Berg SL; Blaney SM
    Clin Cancer Res; 2004 Apr; 10(7):2525-9. PubMed ID: 15073132
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics and metabolism of cyclopentenyl cytosine in nonhuman primates.
    Blaney SM; Balis FM; Hegedus L; Heideman RL; McCully C; Murphy RF; Kelley JA; Poplack DG
    Cancer Res; 1990 Dec; 50(24):7915-9. PubMed ID: 2253232
    [TBL] [Abstract][Full Text] [Related]  

  • 51. DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants.
    Schinazi RF; Mellors J; Bazmi H; Diamond S; Garber S; Gallagher K; Geleziunas R; Klabe R; Pierce M; Rayner M; Wu JT; Zhang H; Hammond J; Bacheler L; Manion DJ; Otto MJ; Stuyver L; Trainor G; Liotta DC; Erickson-Viitanen S
    Antimicrob Agents Chemother; 2002 May; 46(5):1394-401. PubMed ID: 11959574
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetic evaluation of drug interactions with anti-human immunodeficiency virus drugs. V. Effect of soluble CD4 on 2',3'-dideoxycytidine kinetics in monkeys.
    Qian M; Swagler AR; Fong KL; Crysler CS; Mehta M; Gallo JM
    Drug Metab Dispos; 1992; 20(3):396-401. PubMed ID: 1355714
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog.
    Soudeyns H; Yao XI; Gao Q; Belleau B; Kraus JL; Nguyen-Ba N; Spira B; Wainberg MA
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1386-90. PubMed ID: 1929298
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intrathecal administration of topotecan in nonhuman primates.
    Blaney SM; Cole DE; Godwin K; Sung C; Poplack DG; Balis FM
    Cancer Chemother Pharmacol; 1995; 36(2):121-4. PubMed ID: 7767947
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Solid-phase extraction combined with radioimmunoassay for measurement of zalcitabine (2',3'-dideoxycytidine) in plasma and serum.
    Roberts WL; Buckley TJ; Rainey PM; Jatlow PI
    Clin Chem; 1994 Feb; 40(2):211-5. PubMed ID: 8313596
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate- and phosphonoacetate-2',3'-dideoxy-3'-thiacytidine conjugates.
    Charvet AS; Camplo M; Faury P; Graciet JC; Mourier N; Chermann JC; Kraus JL
    J Med Chem; 1994 Jul; 37(14):2216-23. PubMed ID: 8035429
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients.
    Massarella JW; Nazareno LA; Passe S; Min B
    Pharm Res; 1996 Mar; 13(3):449-52. PubMed ID: 8692740
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection.
    Pluda JM; Cooley TP; Montaner JS; Shay LE; Reinhalter NE; Warthan SN; Ruedy J; Hirst HM; Vicary CA; Quinn JB
    J Infect Dis; 1995 Jun; 171(6):1438-47. PubMed ID: 7769277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates.
    Berg SL; Brueckner C; Nuchtern JG; Dauser R; McGuffey L; Blaney SM
    Cancer Chemother Pharmacol; 2007 May; 59(6):743-7. PubMed ID: 16953392
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction.
    Heald AE; Hsyu PH; Yuen GJ; Robinson P; Mydlow P; Bartlett JA
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1514-9. PubMed ID: 8726029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.